Document:

exv4wxfy

Exhibit 4(f)

ASSIGNMENT AND ACCEPTANCE

     Reference is made to the Credit Agreement dated as of July 29, 2003 (as amended and in effect
on the date hereof, the “Credit Agreement”), among Saga Communications, Inc., a Delaware
corporation, the Lenders party thereto, Union Bank of California, N.A., as Syndication Agent, Bank
of America, N.A., as Documentation Agent, and The Bank of New York Mellon, formerly The Bank of New
York, as Administrative Agent. Terms defined in the Credit Agreement are used herein with the same
meanings.

     The Assignor named below hereby sell and assign, without recourse, to the Assignee named
below, and the Assignee hereby purchases and assumes, without recourse, from the Assignor,
effective as of the Assignment Date, the interests set forth below (the “Assigned
Interest”) in the Assignor’s rights and obligations under the Credit Agreement, including,
without limitation, the interests set forth below in the Revolving Commitment of the Assignor on
the Assignment Date and the Revolving Loans owing to the Assignor that are outstanding on the
Assignment Date, together with all of the related participations held by the Assignor in respect of
the Letters of Credit (including its LC Exposure), but excluding accrued interest and fees to and
excluding the Assignment Date. The Assignee hereby acknowledges receipt of a copy of the Credit
Agreement. From and after the Assignment Date, (i) the Assignee shall be a party to and be bound
by the provisions of the Credit Agreement and, to the extent of the Assigned Interest, have the
rights and obligations of a Lender under the Loan Documents and (ii) the Assignor shall, to the
extent of the Assigned Interests, relinquish its rights and be released from its obligations under
the Loan Documents.

     This Assignment and Acceptance is being delivered to the Administrative Agent, together with
(i) if the Assignee is a Foreign Lender, any documentation required to be delivered by the Assignee
pursuant to Section 3.7(e) of the Credit Agreement, duly completed and executed by the Assignee,
and (ii) if the Assignee is not already a Lender under the Credit Agreement, an Administrative
Questionnaire in the form supplied by the Administrative Agent, duly completed by the Assignee.
The Assignor shall pay the fee payable to the Administrative Agent pursuant to Section 10.4(b) of
the Credit Agreement.

     THIS ASSIGNMENT AND ASSUMPTION SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS
OF THE STATE OF NEW YORK.

 

 

Date of
Assignment:   September 29, 2008

Legal Name of Assignor:   The Bank of New York Mellon

Legal Name of Assignee:   ING Capital LLC

Assignee’s Address for Notices:   See attached Administrative Details Form

Effective
Date of Assignment (the “Assignment
Date”):   September 29, 2008

Revolving Commitment Assigned:   $20,000,000.00

Principal Amount of Revolving Loans Assigned:   14,224,000.00

 

 

The terms
set forth above are hereby agreed to:

	 	 	 	 	 
	 	THE BANK OF NEW YORK MELLON, as Assignor

 	 
	 	By:  	 /s/
Lily A. Dastur	 
	 	 	Name:  	 Lily A. Dastur
	 
	 	 	Title:  	 Vice
President
	 
	 

	 	 	 	 	 
	 	ING CAPITAL LLC, as Assignee

 	 
	 	By:  	 /s/
A. Miller	 
	 	 	Name:  	 Annette
Miller-Lewis
	 
	 	 	Title:  	 Associate
	 
	 

The
undersigned hereby consents to the within assignment:1

	 	 	 	 	 
	 	SAGA COMMUNICATIONS, INC.

 	 
	 	By:  	 /s/
Samuel D. Bush	 
	 	 	Name:  	 Samuel
D. Bush
	 
	 	 	Title:  	 
Chief Financial Officer
	 
	 

	 	 	 	 	 
	 	THE BANK OF NEW YORK MELLON, as
Administrative Agent and as Issuing Bank

 	 
	 	By:  	 /s/
Gordon Berger	 
	 	 	Name:  	 Gordon
Berger
	 
	 	 	Title:  	 Managing
Director
	 
	 

 

			
	1.	 	Consents to be included to the extent required by Section 9.04(b)
of the Credit Agreement, which may include Issuing Bank and Swingline Lender
consent.exv10w1

Exhibit
10.1

SECOND AMENDMENT

TO THE AMENDED AND RESTATED

STRATEGIC ALLIANCE AGREEMENT

BY AND BETWEEN
 PENWEST PHARMACEUTICALS CO

AND
 ENDO PHARMACEUTICALS INC

This Second Amendment (this “Amendment”) to the Amended and Restated Strategic Alliance Agreement
dated as of April 2, 2002, and as amended by the Amendment Agreement dated January 7, 2007 (the
“Agreement”) is entered into by and between Penwest Pharmaceuticals Co (“Penwest”) and Endo
Pharmaceuticals Inc. (“Endo”), effective as of July 14, 2008.

Endo and Penwest agree as follows:

1.
Section 1.23 of the Definitions Exhibit to the Agreement is
amended by deleting Section 1.23 in its entirety and inserting the following new Section 1.23 in its place:

1.23 “Formulated TIMERx Price” shall mean Penwest’s contract manufacturing cost (or, if made
internally, its variable costs plus directly allocable (a) fixed and (b) manufacturing
overhead costs relating to the manufacture or acquisition) of the Formulated TIMERx to be
provided to Endo or its Affiliates or sublicensees hereunder, as shall be determined and
adjusted no more often than annually plus the costs directly relating to the quality
control testing referred to in Section 7.2 hereof plus the allocable indirect costs
and fees referred to in the last two sentences of this Section 1.23; provided,
however, that any amounts paid or payable by Penwest for third-party royalties (or for
materials acquisition costs to the extent attributable to third-party intellectual properties
and essentially equivalent to royalties) which are the responsibility of Penwest under
Sections 9.5.1 or 9.5.2 hereof shall not be counted as part of
the Formulated TIMERx Price.
Costs and fees related to and arising out of patent enforcement litigation ensuing from a
third party certifying against a Penwest Patent or a patent covering Penwest Product
Technology held by Penwest and listed in the FDA’s “Orange
Book”-may (to the extent not
reflected in the Certification Budget and the reconciliations under
Section 3.7 hereof) be
included, at the option of Penwest and without prejudice to its other rights, as part of the
allocable indirect costs of the manufacture or acquisition of any Formulated TIMERx provided
for use in the Product; to the extent that such costs and fees are not reimbursed by Endo to
Penwest pursuant to Section 11.7. If any patent applications are filed or prosecuted by
Penwest on Penwest Product Technology, as provided in Section 6.2 hereof, the reasonable
costs thereof, and of the maintenance of any patents

 

 

that issue therefrom, shall (to the extent not reflected in the Certification Budget and
the reconciliations under Section 3.7 hereof) be part of the
allocable indirect costs of
the manufacture or acquisition of any Formulated TIMERx provided for use in the Product
that would be disclosed in whole or in part in such patent or patent application.

2.
Section 11.7 of the Agreement is amended by deleting
Section 11.7 in its entirety and
inserting the following new Section 11.7 in its place:

Section 11.7 Patent Enforcement Litigation. Notwithstanding the foregoing, in the event that
the parties are notified of (1) the filing by a third party of an abbreviated new drug
application (“ANDA”) with the FDA (or the FDA’s acceptance of an ANDA) relating to the
Product or (2) a third party certifying against the patents covering the Product that are
listed in the FDA’s “Orange Book”, then the parties shall cooperate fully with respect to
any ensuing patent enforcement litigation. The costs and fees incurred by or on behalf of
Penwest relating to or in connection with such matters shall be paid by Endo. Payments for
such costs and fees incurred on or after July 1, 2008 shall be made to Penwest or directly
to the thirty party to which such costs and fees are owed within thirty (30) days after
presentation of each invoice to Endo setting forth such costs and fees.

3. Endo shall reimburse Penwest in a single lump sum of $469,567.00 in full satisfaction of
costs and fees incurred by or on behalf of Penwest through April 30, 2008 in connection with the
matters contemplated by Section 11.7 of the Agreement, which amount shall be paid within ten (10)
days of the date of this Amendment. Endo shall reimburse Penwest for cost and fees incurred by or
on behalf of Penwest between May 1, 2008 and June 30, 2008 in connection with the matters
contemplated by Section 11.7 of the Agreement, which amount shall be paid within 45 days of the
presentation of each invoice to Endo.

4. All other terms and conditions of the Agreement as previously amended are
affirmed and remain in full force and effect. The parties agree that all references in the
Agreement to “this Agreement” shall deem to include the provisions of this Amendment.

5. This Amendment shall be governed by, construed and enforced in accordance
with, the laws of the State of New York without regards to its conflict of laws rules.

* * *

 

 

IN WITNESS
WHEREOF, the parties have caused this Amendment to be executed by their duly authorized
representatives.

	 	 	 	 	 	 	 	 	 	 	 
	Endo Pharmaceuticals Inc.	 	 	 	Penwest Pharmaceuticals Co.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	Daniel
J. Carbery	 	 	 	By:	 	Benjamin L. Palleiko	 	 
	 

	 	 

	 	 
	 	 	 	 

	 	 
	

	 	Title:       Sr. VP, Operation
	 	 	 	 	 	Title: Sr. VP, Corporate
Development	 	 
	

	 	Date: July 16, 2008
	 	 	 	 	 	          and Chief Financial Officer	 	 
	

	 	 	 	 	 	 	 	Date: July 16, 2008exv10w1

Exhibit 10.1

	 	 	 	 	 
	 

	 	 	 	
	 
	 	 	 	 
	To:

	 	Arlington Tankers Ltd

Contest Ltd, Concept Ltd, Consul Ltd
	 	 
	 

	 	Concord Ltd, Compatriot Ltd, Companion Ltd

Victory Ltd and Vison Ltd

each of Hayward Building

22 Bermudian Road

Hamilton

HM11

Bermuda
	 	Global Banking & Markets

5-10 Great Tower Street

6th Floor

London EC3P 3HX 

Telephone: + 44 (0) 207 085 5000

Facsimile: + 44 (0) 207 085 7130

www.rbs.com/gbm
	 
	 	 	 	 
	 

	 	Fax No.: +1 441 292 4258 

Attn: Grant Gibbons	 	 
	 
	 	 	 	 
	cc:

	 	Arlington Tankers LLC 

191 Post Road 
Westport 

CT068 80 USA	 	 
	 
	 	 	 	 
	 

	 	Fax No.: +1 203 221 2763

Attn: Ed Terino	 	 

5 August 2008

Dear Sirs

Loan Agreement dated 12 December 2005 (the “Loan Agreement”) made between Arlington Tankers
Ltd as Borrower and The Royal Bank of Scotland plc as Lender relating to a loan facility of
US$229,500,000

You have advised us that you have entered into an exclusivity arrangement with General
Maritime Corporation (“GMC”) for the merger of the Borrower and GMC (the “Merger”) with
ownership of the combined entities split 27%:73% between the Borrower’s current shareholders
and the current shareholders of GMC respectively.

You have requested our approval to the Merger and to the Change of Control arising from the
Merger as required under Clause 19.1(k) of the Loan Agreement.

We write to record our consent to the Merger and the said Change of Control subject to the
following conditions: -

	1	 	confirmation by the Borrower and the Guarantors of the terms of this letter by the
Borrower and the Guarantors signing the acknowledgement at the foot of this letter and
returning the same to us by no later than 8 August 2008 together with such evidence as
we may require in relation to the due authorisation and execution by the Borrower and
the
Guarantors of this letter.
	 
	2	 	there is no further Change of Control following the implementation of the Merger without
our prior written consent.
	 
	3	 	with effect from the end of the current Interest Period (being 30 September 2008) the
Margin shall be increased to 1.25% per annum.
	 
	4	 	upon signing the acceptance of this letter below the Borrower shall pay to ourselves a
fee of US$344,250 (being 0.15% of the current outstanding amount of the Loan)
	 
	5	 	in the event that any prepayment of the Loan is made under Clause 7.5 of the Loan
Agreement within a 2 year period following the date of your signing the acceptance of

 

	 	 	this letter below the Borrower shall pay to us on such prepayment a prepayment fee in
the amount of 1% of the amount prepaid (unless such prepayment fee is waived at our
absolute discretion).
	 
	6	 	the Borrower and the other relevant Security Parties shall enter into such
documentation
supplemental to the Loan Agreement and the other Finance Documents as the Lender
may reasonably require to modify the terms of the Loan Agreement and the other Finance
Documents to reflect the consequential changes to the Group upon the implementation of
the Merger.
	 
	7	 	the Borrower shall reimburse to us on demand all costs, fees and expenses and Taxes
thereon incurred by us in connection with the preparation and execution of this letter
and
in connection with the implementation of the supplemental documentation referred to at
6 above.

This letter shall constitute a Finance Document
for the purposes of the Loan Agreement.

Save for the amendments referred to in this
letter, the terms of the Loan Agreement and the
Finance Documents shall remain unchanged and in full force and effect.

Words and expressions defined in the Loan Agreement shall have the same meaning when used in
this letter.

The provisions of Clause 30 (law and jurisdiction) of the Loan Agreement shall apply to this
letter as if incorporated herein with the logical changes.

Yours faithfully

	 	 	 	 	 
	/s/ Christopher Patrick
 
for and on behalf of

	 	 
	 	 
	The Royal Bank of Scotland plc
	 	 	 	 

accepted and agreed this 25 day of September 2008

	 	 	 	 	 
	/s/ Edward Terino
 
for and on behalf of

Arlington Tankers Ltd

	 	 
	 	 
	 
	 	 	 	 
	/s/ Edward Terino
 
for and on behalf of

Contest Ltd

	 	 
	 	 
	 
	 	 	 	 
	/s/ Edward Terino
 
for and on behalf of

Concept Ltd

	 	 
	 	 
	 
	 	 	 	 

2

 

	 	 	 	 	 
	/s/ Edward Terino
 
for and on behalf of

Consul Ltd

	 	 
	 	 
	 
	 	 	 	 
	/s/ Edward Terino
 
for and on behalf of

Concord Ltd

	 	 
	 	 
	 
	 	 	 	 
	/s/ Edward Terino
 
for and on behalf of

Compatriot Ltd

	 	 
	 	 
	 
	 	 	 	 
	/s/ Edward Terino
 
for and on behalf of

Companion Ltd

	 	 
	 	 
	 
	 	 	 	 
	/s/ Edward Terino
 
for and on behalf of

Victory Ltd

	 	 
	 	 
	 
	 	 	 	 
	/s/ Edward Terino
 
for and on behalf of

Vision Ltd

	 	 
	 	 

3

 

	 	 	 
	 

	 	
	2 September 2008
	 	 
	

Arlington Tankers Ltd

Contest Ltd, Concept Ltd, Consul Ltd

Concord Ltd, Compatriot Ltd, Companion Ltd

Victory Ltd and Vision Ltd

each of Hayward Building

22 Bermudian Road

Hamilton

HM11

Bermuda

	 	Global Banking & Markets

Shipping Business Centre

5-10 Great Tower Street

London EC3P 3HX

Telephone: +44 (0)20 7833 2121

Facsimile: +44 (0)20 7085 7134

www.rbs.com/gbm

Attn: Grant Gibbons

cc Arlington Tankers LLC

191 Post Road

Westport

CT068 80 USA

Attn: Ed Terino

Dear Sirs

Loan Agreement dated 12 December 2005 (the “Loan Agreement”) made between Arlington
Tankers Ltd as Borrower and The Royal Bank of Scotland plc as Lender relating to a loan facility
of US$229,500,000

We refer to our letter dated 5 August 2008 and condition 1 contained therein. Please accept this
letter as our confirmation that we agree to extend the date for the signing of the acknowledgement to no
later than 12 September 2008.

All other terms and conditions referred to in the 5 August 2008 letter remain unchanged.

Yours faithfully

/s/ Christopher Patrick 

Christopher Patrick

Director, Ship Finance Portfolio Management

Shipping Business Centre

Direct tel: +44 207 085 7022   Direct fax: +44 207 085 7142

Email: christopher.patrick@rbs.com

The Royal Bank of Scotland plc. Registered
in Scotland No. 90312. Registered Office. 36 St Andrew Square, Edinburgh EH2 2YB.

Authorised and regulated by the Financial Services Authority

The Royal Bank of Scotland plc is an authorised agent of ABN AMRO Bank N. V.

 

 

	 	 	 
	 

	 	
	23 September 2008
	 	 
	

Arlington Tankers Ltd

Contest Ltd, Concept Ltd, Consul Ltd

Concord Ltd, Compatriot Ltd, Companion Ltd

Victory Ltd and Vision Ltd

each of Hayward Building

22 Bermudian Road

Hamilton

HM 11

Bermuda

	 	Global Banking & Markets

Shipping Business Centre

5-10 Great Tower Street

London EC3P 3HX

Telephone: +44 (0)20 7833 2121

Facsimile: +44 (0)20 7085 7134

www.rbs.com/gbm

Attn: Grant Gibbons

cc Arlington Tankers LLC

191 Post Road

Westport

CT068 80 USA

Attn: Ed Terino

Dear Sirs

Loan Agreement dated 12
December 2005 (the “Loan Agreement”) made between Arlington
Tankers Ltd as Borrower and The Royal Bank of Scotland plc as Lender relating to a loan facility
of US$229,500,000

We refer to our letters dated 5 August 2008 and 2 September 2008 and condition 1 contained
therein. Please accept this letter as our confirmation that we agree to extend the date for the
signing of the acknowledgement to no later than 26 September 2008.

Additionally, in relation to points 2 to 6 contained in our letter dated 5 August 2008 please
note that they will become effective upon closing of the Merger.

All other terms and conditions referred to in the 5 August 2008 letter remain unchanged.

Yours faithfully

/s/ Christopher Patrick 

Christopher Patrick

Director, Ship Finance Portfolio Management

Shipping Business Centre

Direct tel: +44 207 085 7022   Direct fax: +44 207 085 7142

Email: christopher.patrick@rbs.com

The Royal Bank of Scotland plc. Registered in
Scotland No. 90312. Registered Office. 36 St Andrew Square, Edinburgh EH2 2YB.

Authorised and regulated by the Financial Services Authority

The Royal Bank of Scotland plc is an authorised agent of ABN AMRO Bank N.V.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}]]